BIOCRYST PHARMACEUTICALS INC
BCRX· Nasdaq· Biological Products, (No Diagnostic Substances)
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- 39.4%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +117.9%
We record prices for the companies we cover; BCRX is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 218.6M
- Revenue
- $874.8M
- Free cash flow
- $344.9M
- Owner earnings
- $259.8M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- 39.0%
- Net
- 30.2%
- Free cash flow
- 39.4%
- Owner earnings
- 29.7%
- Stock pay
- 9.7%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- –
- ROE, 5 yr avg
- –
Growth (CAGR)
- Revenue, 3 yr
- 47.8%
- Revenue, 5 yr
- 117.9%
- Revenue, 9 yr
- 47.6%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 9 yr
- –
Financial health · FY2025
- Cash and investments
- $274.7M
- Total debt
- $0
- Net cash
- $274.7M
- Debt/Equity
- –
- Debt/FCF
- 0.0x
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 5.5%
Financials: ten years from the 10-Ks
Revenue
$874.8M
+47.6% a year over 9 years
FY2016FY2025
Margins
Operating39.0%Net30.2%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow$344.9MOwner earnings$259.8M
FY2025
FY2016FY2025
Diluted shares
218.6M
+196.6% over 9 years, net dilution
FY2016FY2025
Net cash
$274.7M
$274.7M more cash than debt
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Revenue growth | -45.4% | -4.4% | -18.0% | 136.5% | -63.5% | 782.4% | 72.3% | 22.4% | 36.0% | 94.1% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Net income | -$55.1M | -$65.8M | -$101.3M | -$108.9M | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| Net margin | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| Diluted EPS | – | – | – | – | $-1.09 | $-1.03 | $-1.33 | $-1.18 | $-0.43 | $1.21 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | -$53.4M | -$41.1M | -$92.6M | -$89.6M | -$135.1M | -$142.2M | -$161.8M | -$95.1M | -$52.0M | $347.4M |
| Capital expenditure | $5.3M | $328.0K | $366.0K | $343.0K | $514.0K | $2.4M | $1.4M | $2.2M | $1.1M | $2.5M |
| Free cash flow | -$58.7M | -$41.5M | -$92.9M | -$89.9M | -$135.6M | -$144.5M | -$163.2M | -$97.3M | -$53.1M | $344.9M |
| Stock-based compensation | $8.5M | $12.6M | $9.4M | $17.7M | $14.8M | $34.6M | $44.7M | $55.6M | $65.4M | $85.1M |
| Owner earnings? | -$67.2M | -$54.1M | -$102.3M | -$107.6M | -$150.4M | -$179.2M | -$207.9M | -$152.9M | -$118.6M | $259.8M |
| Free cash flow per share | $-0.80 | $-0.49 | $-0.90 | $-0.78 | $-0.81 | $-0.81 | $-0.88 | $-0.51 | $-0.26 | $1.58 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – | – | – |
| Diluted shares | 73.7M | 84.5M | 103.2M | 115.6M | 167.3M | 179.1M | 185.9M | 192.2M | 206.7M | 218.6M |
| Share count change? | 1.1% | 14.6% | 22.2% | 12.0% | 44.7% | 7.1% | 3.8% | 3.4% | 7.5% | 5.7% |
| Balance sheet | ||||||||||
| Cash and equivalents | $22.1M | $50.3M | $26.7M | $114.2M | $272.1M | $504.4M | $304.8M | $110.6M | $104.7M | $89.7M |
| Short-term investments | $32.5M | $64.1M | $77.7M | $22.1M | $28.2M | $3.2M | $119.5M | $278.3M | $216.1M | $185.0M |
| Total debt | $23.0M | $23.0M | $30.0M | $0 | $119.7M | $136.1M | $231.6M | $303.2M | $314.9M | $0 |
| Net debt | -$31.6M | -$91.4M | -$74.5M | -$136.2M | -$180.6M | -$371.5M | -$192.7M | -$85.8M | -$6.0M | -$274.7M |
| Shareholders' equity | $1.6M | $83.8M | $49.2M | $38.3M | -$19.3M | -$107.0M | -$294.6M | -$455.5M | -$475.9M | -$119.2M |
Latest filings
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Earnings release |
| 2026-05-06 | 10-Q | Quarterly report |
| 2026-05-06 | 8-K | Earnings release |
| 2026-04-23 | DEF 14A | Proxy statement |
| 2026-02-26 | 10-K | Annual report |
| 2026-02-26 | 8-K | Earnings release |
| 2026-01-12 | 8-K | Earnings release |
| 2025-11-04 | 10-Q | Quarterly report |
| 2025-11-03 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
